98.09
+0.48(+0.49%)
Currency In USD
| Previous Close | 97.61 |
| Open | 97.61 |
| Day High | 98.28 |
| Day Low | 96.72 |
| 52-Week High | 99.04 |
| 52-Week Low | 43.57 |
| Volume | 404,946 |
| Average Volume | 706,803 |
| Market Cap | 6.52B |
| PE | -32.59 |
| EPS | -3.01 |
| Moving Average 50 Days | 78.6 |
| Moving Average 200 Days | 62.82 |
| Change | 0.48 |
If you invested $1000 in Rhythm Pharmaceuticals, Inc. (RYTM) since IPO date, it would be worth $3,992.27 as of August 18, 2025 at a share price of $98.09. Whereas If you bought $1000 worth of Rhythm Pharmaceuticals, Inc. (RYTM) shares 5 years ago, it would be worth $5,339.68 as of August 18, 2025 at a share price of $98.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
GlobeNewswire Inc.
Jul 22, 2025 8:01 PM GMT
BOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
GlobeNewswire Inc.
Jul 12, 2025 10:00 PM GMT
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase 3 TRANSCEND study underscore potential efficacy of setmelanotide, including with prior use or concomitant use of
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
GlobeNewswire Inc.
Jul 10, 2025 10:21 AM GMT
BOSTON, July 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today a